PPARA and Parkinson disease: By analyzing the geometric relationships between PPAR agonists, mitochondrial enhancers, and circadian modulators, GDL models may identify synergistic combinations (e.g., pioglitazone with melatonin) to address multifactorial PD-RBD pathology while minimizing adverse effects (94, 95).